Impact of occult hepatitis B virus infection on outcome after resection for non-B non-C hepatocellular carcinoma

Journal of Surgical Research

Volumn 193, Issue 1, 2015, Pages 153-160

  Wu, Zhen Feng ^a   Xu, Zhe ^a   Li, Wei Su ^a   Zhang, Hai Bin ^b   Yang, Ning ^b   Yao, Xue Quan ^a   Liu, Fu Kun ^a   Yang, Guang Shun ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Non B non C hepatocellular carcinoma; Occult hepatitis B virus infection; Prognostic factor; Surgery

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PORTAL HYPERTENSION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; THROMBOCYTE COUNT; BLOOD; CARCINOMA, HEPATOCELLULAR; EPIDEMIOLOGY; FACTUAL DATABASE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; SURVIVAL ANALYSIS;

EID: 84925030554     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2014.07.021     Document Type: Article

References (39)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277.
3. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448.
4. Kaibori M, Ishizaki M, Matsui K, Kwon AH. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg 2012; 204:300.
5. Utsunomiya T, Shimada M. Molecular characteristics of noncancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res 2011;41:711.
6. Yotsuyanagi H, Shintani Y, Moriya K, et al. Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus. J Infect Dis 2000;181:1920.
7. Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res 2012;42:368.
8. Ikeda K, Kobayashi M, Someya T, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009;16:437.
9. Tokushige K, Hashimoto E, Horie Y, et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol 2011;46:1230.
10. Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 2012;32:30.
11. Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349.
12. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007;46:160.
13. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002;9:243.
14. Raimondo G, Navarra G, Mondello S, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008;48:743.
15. Berasain C, Betes M, Panizo A, et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 2000; 47:429.
16. Chan HL, Tsang SW, Leung NW, et al. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol 2002;97:1211.
17. Cho EJ, Kwack MS, Jang ES, et al. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion 2011; 84(Suppl 1):17.
18. Kusakabe A, Tanaka Y, Orito E, et al. A weak association betweenoccultHBVinfection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol 2007;42:298.
19. Kondo R, Nakashima O, Sata M, et al. Pathological characteristics of patients who develop hepatocellular carcinoma with negative results of both serous hepatitis B surface antigen and hepatitis C virus antibody. Hepatol Res; 2013. http://dx.doi.org/10.1111/hepr.12219.
20. Chemin I, Guillaud O, Queyron PC, Trepo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol 2009;51:824.
21. Yang T, Zhang J, Lu JH, et al. A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. J Cancer Res Clin Oncol 2011;137:739.
22. Wu ZF, Zhang HB, Yang N, et al. Postoperative adjuvant transcatheter arterial chemoembolisation improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors: results of a large monocentric series. Eur J Surg Oncol 2012;38:602.
23. Wu CC, Ho WL, Chen JT, et al. Hepatitis viral status in patients undergoing liver resection for hepatocellular carcinoma. Br J Surg 1999;86:1391.
24. Koike Y, Shiratori Y, Sato S, et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000;32:1216.
25. Abe H, Yoshizawa K, Kitahara T, et al. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol 2008;43:967.
26. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010;16:1436.
27. Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809.
28. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001;34:194.
29. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652.
30. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479.
31. Yokoi Y, Suzuki S, Baba S, et al. Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection. J Gastroenterol 2005;40:274.
32. Dohmen K, Shigematsu H, Irie K, Ishibashi H. Comparison of the clinical characteristics among hepatocellular carcinoma of hepatitis B, hepatitis C and non-B non-C patients. Hepatogastroenterology 2003;50:2022.
33. Pawlik TM, Poon RT, Abdalla EK, et al. Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg 2004;8:794. discussion 804e795.
34. Takenaka K, Yamamoto K, Taketomi A, et al. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology 1995;22:20.
35. Chang ML, Lin YJ, Chang CJ, et al. Occult and overt HBV co-infections independently predict postoperative prognosis in HCV-associated hepatocellular carcinoma. PLoS One 2013; 8:e64891.
36. Nishikawa H, Osaki Y, Arimoto A, et al. Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma. Anticancer Res 2013;33:2211.
37. Myronovych A, Murata S, Chiba M, et al. Role of platelets on liver regeneration after 90% hepatectomy in mice. J Hepatol 2008;49:363.
38. Watanabe M, Murata S, Hashimoto I, et al. Platelets contribute to the reduction of liver fibrosis in mice. J Gastroenterol Hepatol 2009;24:78.
39. Matsuo R, Ohkohchi N, Murata S, et al. Platelets strongly induce hepatocyte proliferation with IGF-1 and HGF in vitro. J Surg Res 2008;145:279.